Where does tirzepatide come from? Lilly's LY3298176

Where does tirzepatide come from?

Tirzepatide is a synthetic peptide designed at Eli Lilly and first published under the research code LY3298176 (Coskun et al., Molecular Metabolism, 2018). Tirzepatide is not extracted from a plant or an animal. Chemists built the molecule on the sequence of GIP, a hormone made in the human gut. The tirzepatide research guide follows the broader evidence record. This article follows a narrower route: an edited hormone sequence became a laboratory code, entered human studies, acquired a generic name, and reached the 2022 US medicine label as Mounjaro.

The sections below separate the developer, the code name, the molecular construction, the trial path, and the limits of the published record.

Who developed tirzepatide?

Tirzepatide was developed by Eli Lilly through the research program reported by Coskun et al. in Molecular Metabolism in 2018. The paper names the molecule LY3298176 and describes its design and early testing. The same report covers the first-in-human program registered as NCT02759107. In that program, 142 people received at least one dose between 11 May 2016 and 26 June 2017 at two sites, one in the USA and one in Singapore (Coskun et al., Molecular Metabolism, 2018). These records tie the molecule's published origin to Lilly rather than to a natural source.

The discovery paper does more than attach a company name. It joins the chemistry, laboratory receptor work, and first human study in one published trail. That trail shows how the candidate moved from molecular design into clinical research while it still carried its internal code.

What is LY3298176?

Tirzepatide and LY3298176 are the same molecule at different naming stages. LY3298176 was Eli Lilly's internal research code in the 2018 discovery paper. Tirzepatide became the generic name used through the later clinical record. Mounjaro became the US brand name when the medicine received initial US approval in 2022, according to the 2022 FDA label for Mounjaro. The order matters: research code, generic name, then approved brand. Readers looking for a broader comparison can see how the three molecules differ without treating those names as three versions of tirzepatide.

Names can tell readers which part of the record they are holding. A discovery paper may say LY3298176. A scientific article or trial record may say tirzepatide. A US medicine label may say Mounjaro and identify tirzepatide as its active ingredient. The molecule is shared; the regulatory and document context is not.

What is tirzepatide made of?

Tirzepatide is one linear chain of 39 amino acids built on a GIP backbone, with a C20 fatty diacid attached at Lys20 through a linker (Coskun et al., Molecular Metabolism, 2018). Lys20 means the twentieth position is a lysine used as the attachment point. Aib, a non-standard amino acid used instead of a natural one, appears at positions 2 and 13. The fatty diacid is a fatty-acid chain that helps the peptide stick to blood protein. An amidated C-terminus means the tail end is capped. The reported molecular weight is 4810.52 Da (Coskun et al., Molecular Metabolism, 2018).

Willard et al. wrote that tirzepatide was discovered by engineering GLP-1 activity into the GIP sequence (JCI Insight, 2020). The laboratory results showed equal affinity to natural GIP at the GIP receptor and roughly five-fold weaker activity than natural GLP-1 at the GLP-1 receptor (Willard et al., JCI Insight, 2020). That imbalance was part of the design, not evidence that the molecule was harvested from either hormone.

The sequence and its attached chain explain more about origin than a formula alone. A nearby article gives retatrutide's molecular formula, but tirzepatide follows its own design record and has the formula C225H348N48O68 (Coskun et al., Molecular Metabolism, 2018).

Is tirzepatide made from a natural source?

Tirzepatide is not identified in the published record as a plant extract or an animal isolate. Tirzepatide is a synthetic peptide built by editing the sequence of human GIP (Coskun et al., Molecular Metabolism, 2018; Willard et al., JCI Insight, 2020). The natural part is the starting idea: the human gut already makes GIP as a signalling hormone. The finished molecule is different. Chemists changed selected amino acids and attached a fatty diacid chain. The result is a designed laboratory molecule based on a human hormone sequence, not that hormone collected from the body.

A useful distinction is the difference between copying a pattern and collecting a substance. A written melody can inspire a new arrangement without being taken from a live performance. In the same way, the GIP sequence provided a molecular pattern. The Lilly program then edited that pattern into LY3298176.

How did tirzepatide go from a lab code to an approved medicine?

Tirzepatide moved from the 2018 LY3298176 discovery paper into a 26-week Phase 2 trial in type 2 diabetes, then the 40-week Phase 3 monotherapy trial SURPASS-1, before US approval as Mounjaro in 2022. The Phase 2 trial randomised 318 people and reported HbA1c changes from −1.06% to −1.94%, compared with −0.06% for placebo (Frías et al., Lancet, 2018). SURPASS-1 randomised 478 people across 52 centres and reported HbA1c changes from −1.87% to −2.07%, compared with +0.04% for placebo (Rosenstock et al., Lancet, 2021).

The stages answer different questions. Discovery work explains how the molecule was built. Later trials test defined outcomes in defined groups. The 2022 FDA label then records Mounjaro as a GIP and GLP-1 receptor agonist with initial US approval in 2022. The label also carries a boxed warning about thyroid C-cell tumours seen in rats.

Research-use material sold for laboratory work is not that approved medicine. The listing for tirzepatide reference material gives lot, certificate-of-analysis, and release-status context for laboratory paperwork. The wider timeline for how long retatrutide has been studied follows a separate molecule and should not be folded into tirzepatide's record.

Evidence limits

What does the research not show?

The 2022 FDA label for Mounjaro does not establish Australian TGA status and does not make Form Laboratories material Mounjaro. Research-use tirzepatide is not a medicine, not a substitute for one, and not for human or animal use. The label describes an approved US product with its own manufacturing and regulatory record; it does not transfer that status to a laboratory reference item.

Eli Lilly sponsored all four papers, and most of the authors were Lilly employees.